Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Gujarat, Uttarakhand discoms score grade A in performance rankings

2018-07-03 moneycontrol
Power distribution companies of Gujarat and Uttarakhand have scored the top grade in the rankings of discoms for 2016-17, according to a report. As many as 41 state utilities were ranked on the basis of aggregate technical and commercial losses (AT&C), billing efficiency and financial parameters.
PFC PWQFY 532810

7
Waste-to-energy projects: Banks taking a guarded approach

2018-06-20 moneycontrol
Although the Centre has prepared and planned a policy to boost the use of bio-fuels, most enterprises have been concerned over funding difficulties for waste-to-energy projects. Even banks have maintained a cautious and guarded approach over funding these power projects, especially in new sectors such as bio-fuels.
PFC PWQFY ICICIBANK 532174 IBN 532810

0
COMMENT- PRAAPTI: Transparency or tokenism? You decide

2018-06-19 moneycontrol
Late last month, RK Singh, minister of state in charge of power, launched the PRAAPTI app and web portal. The idea was to bring in transparency related to electricity payments to power generators.
PFC PWQFY 532810

0
Power Finance CMD sees turnaround in stressed power assets in 2-3 years

2018-06-03 livemint
Mumbai: As power demand increases and old thermal plants are phased out, even stranded power projects with coal linkages will see a turnaround, a top official at Power Finance Corp. Ltd said.
PFC PWQFY 532810

1
Allahabad HC stays central bank circular on NPAs in power sector

2018-06-01 moneycontrol
The Allahabad High Court has stayed Reserve Bank of India’s February 12 circular on a resolution on non-performing assets (NPAs) in the power sector.
PFC PWQFY 532810 SBAZ

1
SBI, Power Finance Corp working to resolve 11 power projects under SBI Samadhan Scheme

2018-05-31 moneycontrol
Power Finance Corporation (PFC) is working with the country’s biggest lender, State Bank of India (SBI), and others to resolve 11 stressed power projects among other resolution plans.
PFC PWQFY 532810 SBAZ NTPZY

0
Power Finance Corp., Ltd. ADR 2018 Q4 - Results - Earnings Call Slides

2018-05-29 seekingalpha
The following slide deck was published by Power Finance Corp., Ltd. ADR in conjunction with their 2018 Q4 earnings call.
PWQFY PFC 532810

7
ICICI-led group to sell Essar Power arm to recover dues

2018-05-27 freepressjournal.in
Mumbai : An ICICI Bank-led consortium, which includes Rural Electrification Corp, Power Finance Corp, Punjab National Bank and IDFC, is looking to sell Essar Power MP, to recover Rs 6,600 crore of dues, sources said.
PFC PWQFY ICICIBANK PNJZY 532461 532174 IBN PNB 532955 RECLTD 532810

Related Articles

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

NVRO: Nevro Corp Analysis and Research Report

2018-07-06 - Asif

Overview Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company's proprietary paresthesia-free HF10TM therapy, delivered by its Senza system, was demonstrated in its SENZA-RCT study to be superior to traditional SCS therapy with it being nearly twice as successful in treating back pain and 1.5 times as successful in treating leg pain when compared to traditional SCS therapy. Comparatively, traditional SCS therapy has limited efficacy in treating back pain and is used primarily for treating leg pain, limiting its market adoption. The company's SENZA-RCT study, along with its European studies, represents what the company believe is the most robust body of clinical evidence for any SCS therapy. The compa...

Silicon Investor Message Boards

This table lists all message boards related to NSE:PFC / POWER FINANCE CORPORATION LTD. on message board site Silicon Investor.

American Pacific (APFC)-Specialty Chemicals PFCE
PFCB: P.F. Changu0027s China Bistro PFCK Gets $50 million cash infusion
PFCK: Peacock Financial Corp. Lotus Pacific Inc. (LPFC)
New CMGI in Development look at PFCK PFCS
PF Changu0027s China Bistro (PFCB) Pacific Galleon Resources